Chongqing Lummy Pharmaceutical Co., Ltd. (SHE:300006)
China · Delayed Price · Currency is CNY 6.21
+0.03 (0.49%)
Apr 15, 2026, 3:08 PM CST
SHE:300006 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Operating Revenue | 761.96 | 782.54 | 874.25 | 865.46 | 1,211 |
Other Revenue | 13.73 | 13.06 | 21.34 | 19.13 | 14.61 |
| 775.69 | 795.6 | 895.59 | 884.59 | 1,225 | |
Revenue Growth (YoY) | -2.50% | -11.16% | 1.24% | -27.80% | -22.63% |
Cost of Revenue | 355.32 | 296.54 | 283.15 | 238.66 | 380.93 |
Gross Profit | 420.37 | 499.06 | 612.44 | 645.93 | 844.3 |
Selling, General & Admin | 440.12 | 531.63 | 596.69 | 659.59 | 854.25 |
Research & Development | 62.5 | 64.73 | 99.81 | 80.65 | 100.2 |
Other Operating Expenses | -8.79 | -24.58 | -25.67 | 17.18 | 24.7 |
Operating Expenses | 498.12 | 573.84 | 669.15 | 751.82 | 977.73 |
Operating Income | -77.75 | -74.79 | -56.71 | -105.89 | -133.43 |
Interest Expense | -13.76 | -11.13 | -12.47 | -20.35 | -32.08 |
Interest & Investment Income | 24.8 | 29.65 | 121.66 | 18.71 | 61.45 |
Currency Exchange Gain (Loss) | -0.96 | 0.44 | 0.57 | 2.77 | -0.77 |
Other Non Operating Income (Expenses) | -0.74 | -9.31 | -5.48 | -45.43 | -25.12 |
EBT Excluding Unusual Items | -68.42 | -65.13 | 47.56 | -150.19 | -129.95 |
Gain (Loss) on Sale of Investments | -21.14 | -18.88 | -1.28 | - | - |
Gain (Loss) on Sale of Assets | 0.03 | 0.49 | 0.45 | 0.26 | -0.03 |
Asset Writedown | -62.35 | -25.75 | -0.71 | -0.1 | -0.51 |
Legal Settlements | - | 30.11 | -51.76 | - | - |
Other Unusual Items | 5.07 | 3.61 | 9.34 | 74.78 | 24.52 |
Pretax Income | -146.81 | -75.54 | 3.59 | -75.25 | -105.96 |
Income Tax Expense | -20.28 | 4.55 | 13.61 | 1.04 | -0.03 |
Earnings From Continuing Operations | -126.53 | -80.09 | -10.02 | -76.28 | -105.94 |
Minority Interest in Earnings | -8.17 | -7.72 | 1.09 | 7.58 | 5.41 |
Net Income | -134.71 | -87.8 | -8.93 | -68.71 | -100.53 |
Net Income to Common | -134.71 | -87.8 | -8.93 | -68.71 | -100.53 |
Shares Outstanding (Basic) | 1,056 | 1,055 | 1,050 | 1,055 | 995 |
Shares Outstanding (Diluted) | 1,056 | 1,055 | 1,050 | 1,055 | 995 |
Shares Change (YoY) | 0.03% | 0.48% | -0.48% | 6.03% | 22.54% |
EPS (Basic) | -0.13 | -0.08 | -0.01 | -0.07 | -0.10 |
EPS (Diluted) | -0.13 | -0.08 | -0.01 | -0.07 | -0.10 |
Free Cash Flow | -15.71 | 106.41 | 22.21 | -11.05 | 69.63 |
Free Cash Flow Per Share | -0.01 | 0.10 | 0.02 | -0.01 | 0.07 |
Gross Margin | 54.19% | 62.73% | 68.38% | 73.02% | 68.91% |
Operating Margin | -10.02% | -9.40% | -6.33% | -11.97% | -10.89% |
Profit Margin | -17.37% | -11.04% | -1.00% | -7.77% | -8.21% |
Free Cash Flow Margin | -2.02% | 13.37% | 2.48% | -1.25% | 5.68% |
EBITDA | -31.17 | -24.43 | 8.76 | -35.29 | -63.41 |
EBITDA Margin | -4.02% | -3.07% | 0.98% | -3.99% | -5.18% |
D&A For EBITDA | 46.58 | 50.35 | 65.47 | 70.6 | 70.01 |
EBIT | -77.75 | -74.79 | -56.71 | -105.89 | -133.43 |
EBIT Margin | -10.02% | -9.40% | -6.33% | -11.97% | -10.89% |
Effective Tax Rate | - | - | 378.71% | - | - |
Revenue as Reported | 775.69 | 795.6 | 895.59 | 884.59 | 1,225 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.